Clinical Cancer Research Joint Metastasis Research Society-AACR Conference on Metastasis Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Celetti, A.
Right arrow Articles by Santoro, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Celetti, A.
Right arrow Articles by Santoro, M.
Clinical Cancer Research Vol. 11, 8019-8027, November 15, 2005
© 2005 American Association for Cancer Research


Human Cancer Biology

Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness

Angela Celetti1, Domenico Testa2, Stefania Staibano3, Francesco Merolla1, Valentina Guarino1, Maria Domenica Castellone1, Renata Iovine2, Gelsomina Mansueto3, Pasquale Somma3, Gaetano De Rosa3, Vieri Galli2, Rosa Marina Melillo1 and Massimo Santoro1

Authors' Affiliations: 1 Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche/Dipartimento di Biologia e Patologia Cellulare e Molecolare, 2 Dipartimento Assistenziale di Otorinolaringoiatria e Scienze Affini, and 3 Dipartimento di Scienze Biomorfologiche e Funzionali, University of Naples "Federico II," Naples, Italy

Requests for reprints: Massimo Santoro, Dipartimento di Biologia e Patologia Cellulare e Molecolare, University of Naples "Federico II," via S. Pansini 5, 80131 Naples, Italy. Phone: 39-81-7463056; Fax: 39-81-7463037; E-mail: masantor{at}unina.it.

Purpose: Osteopontin is a secreted cytokine that binds to the cell surface CD44v6 receptor. We studied osteopontin and CD44v6 expression in laryngeal squamous cell carcinomas and correlated osteopontin expression levels with clinicopathologic tumor features.

Experimental Design: We used immunohistochemistry, immunoblotting, and reverse transcription-PCR to study osteopontin expression in 58 laryngeal squamous cell carcinomas. Cultured squamous carcinoma cells were treated with exogenous osteopontin or with RNA interference to knockdown osteopontin expression.

Results: Osteopontin expression was higher in all the invasive carcinomas than in patient-matched normal mucosa. Its expression levels were significantly correlated with tumor stage and grade and with the presence of lymph node and distant metastases. Osteopontin positivity was negatively correlated with overall survival (P = 0.03). Osteopontin expression was paralleled by intense cell surface reactivity for CD44v6. Treatment of squamous carcinoma cells with recombinant osteopontin sharply increased proliferation and Matrigel invasion in comparison with the untreated cells parallel to activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase signaling cascade. Osteopontin knockdown by RNA interference, anti-CD44 antibodies, and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibition prevented these effects.

Conclusions: These results identify osteopontin as a marker and a potential therapeutic target in cases of aggressive laryngeal squamous cell carcinomas.




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
M. Suzuki, E. Mose, C. Galloy, and D. Tarin
Osteopontin Gene Expression Determines Spontaneous Metastatic Performance of Orthotopic Human Breast Cancer Xenografts
Am. J. Pathol., August 1, 2007; 171(2): 682 - 692.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
M. Bloomston, E. C. Ellison, P. Muscarella, O. Al-Saif, E. W. Martin, W. S. Melvin, and W. L. Frankel
Stromal Osteonectin Overexpression Is Associated with Poor Outcome in Patients with Ampullary Cancer
Ann. Surg. Oncol., January 1, 2007; 14(1): 211 - 217.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
F. J White, R. C Burghardt, J. Hu, M. M Joyce, T. E Spencer, and G. A Johnson
Secreted phosphoprotein 1 (osteopontin) is expressed by stromal macrophages in cyclic and pregnant endometrium of mice, but is induced by estrogen in luminal epithelium during conceptus attachment for implantation.
Reproduction, December 1, 2006; 132(6): 919 - 929.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Petrik, P. W. Lavori, H. Cao, Y. Zhu, P. Wong, E. Christofferson, M. J. Kaplan, H. A. Pinto, P. Sutphin, A. C. Koong, et al.
Plasma Osteopontin Is an Independent Prognostic Marker for Head and Neck Cancers
J. Clin. Oncol., November 20, 2006; 24(33): 5291 - 5297.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2005 by the American Association for Cancer Research.